Sotorasib associated with tacrolimus and everolimus: A significant drug interaction in lung transplant patients - Université Grenoble Alpes Accéder directement au contenu
Article Dans Une Revue Transplant Immunology Année : 2022

Sotorasib associated with tacrolimus and everolimus: A significant drug interaction in lung transplant patients

Léa Liaigre
  • Fonction : Auteur
Pauline Orhon
  • Fonction : Auteur
Amandine Briault
  • Fonction : Auteur
Philippe Romand
  • Fonction : Auteur
Loic Falque
  • Fonction : Auteur
Christel Saint Raymond
  • Fonction : Auteur
Bruno Degano
  • Fonction : Auteur
Pierrick Bedouch
  • Fonction : Auteur

Résumé

The management of immunosuppressors in solid organ transplantation requires pharmacological therapeutic monitoring with regular adaptation of the dosage to the residual level. An obvious cause of these fluctuations is drug interactions, particularly for mTOR inhibitors and anti-calcineurin drugs, which are highly metabolized by cytochromes P450. A 72-year-old lung transplanted man, treated by tacrolimus and everolimus in the long term, had his residual immunosuppressor levels unbalanced by the introduction of sotorasib, which is used for metastatic pulmonary adenocarcinoma. This imbalance is explained by the fact that sotorasib is an inducer of CYP3A4 and an inhibitor of PGP, but the strength of the interaction has never been studied. This will have required a threefold increase in dosages and weekly monitoring before satisfactory residual levels were achieved.

Dates et versions

hal-04552754 , version 1 (19-04-2024)

Identifiants

Citer

Léa Liaigre, Quentin Perrier, Pauline Orhon, Amandine Briault, Philippe Romand, et al.. Sotorasib associated with tacrolimus and everolimus: A significant drug interaction in lung transplant patients. Transplant Immunology, 2022, 74, pp.101678. ⟨10.1016/j.trim.2022.101678⟩. ⟨hal-04552754⟩

Collections

UGA LBFA
3 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More